PWPeter F. Weller

Peter F. Weller

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Peter F. Weller has a total of 141 co-authors. Here are the top co-authors by number of shared publications:

  • Rossana Correa Netto de Melo

    Laboratory of Cellular Biology, Department of Biology, Institute of Biological Sciences, Federal University of Juiz de Fora, Juiz de Fora, MG, Brazil

    26 shared publications
  • Ann M. Dvorak

    11 shared publications
  • Lisa A. Spencer

    Division of Allergy and Inflammation, Harvard Medical School, Beth Israel Deaconess Medical Center, CLS 943, 330 Brookline Avenue, Boston, Massachusetts 02215, USA

    11 shared publications
  • Praveen Akuthota

    Division of Pulmonary, Critical Care, and Sleep Medicine University of California San Diego La Jolla California USA

    6 shared publications
  • Josiane S. Neves

    Division of Allergy and Inflammation, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA

    5 shared publications
  • Sandra A. C. Perez

    Laboratory of Inflammation, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, RJ, Brazil

    5 shared publications

Latest Publications

  • Sombrero vesicles: from overlooked structures to primary mediators of eosinophil secretion

    by Rossana C N Melo, Peter F Weller

    Eosinophils, cells of the innate immune system, have a unique architecture, which includes morphologically complex secretory granules and a prominent, activation-responsive vesiculotubular system. In human eosinophils, this system is collectively termed eosinophil sombrero vesicles (EoSVs) because of its peculiar morphology feasibly identifiable by transmission electron microscopy. Considered as “microgranules” or “small granules” in the past, EoSVs are currently defined as active components of the eosinophil secretory pathway, sprouting from specific granules and trafficking granule-derived products in the eosinophil cytoplasm. Eosinophil secretory proteins associated with EoSVs include cationic proteins, cytokines, cytokine receptors, membrane fusion complexes, and tetraspanins. Beyond the intracellular landscape, emerging evidence has revealed a more complex functional repertoire for EoSVs. This review offers an overview of EoSVs as key participants in the mechanisms of eosinophil secretion during immune responses, incorporating the recent understanding of these transport carriers as extracellular vesicles, potentially implicated in the traffic of eosinophil products in the extracellular medium and intercellular communication.

  • Open Access

    Humanized FcεRI Expressed on Mouse Eosinophils Mediates IgE-Facilitated Eosinophil Antigen Presentation

    by Haibin Wang, Jean-Pierre Kinet, Peter F. Weller

    High-affinity IgE receptors (FcεRI) are expressed on human blood eosinophils and may be upregulated on eosinophils at sites of allergic inflammation including atopic dermatitis and allergic asthma. FcεRI engagement, however, fails to elicit “effector” responses from eosinophils. Thus, a functional role for FcεRI on eosinophils has been uncertain. We evaluated the role of FcεRI in enhancing eosinophil antigen presentation in vivo by using humanized FcεRI α chain (hFcεRIα) transgenic mice. Eosinophils from hFcεRIα transgenic mice expressed humanized FcεRIα, with higher levels of eosinophils from the bronchoalveolar lavage of experimental asthma than those from polymyxin-elicited peritoneal lavage. The hFcεRIα-bearing eosinophils instilled intratracheally (i.t.) into recipient wild-type mice migrated from airways into paratracheal lymph nodes (pLNs) and spleens. Eosinophils, pretreated in vitro with nitrophenyl-ovalbumin ((NP)-OVA) and anti-NP human IgE complexes and instilled i.t., presented NP antigen via hFcεRIα to T cells more effectively than those pretreated with NP-OVA only, as assessed by pLN cell proliferation. IgE/FcεRIα-facilitated eosinophil antigen presentation resulted in increased IL-4 but not INF-γ production by pLN cells, with a bias towards Th2 cytokine production. Furthermore, cross-linking hFcεRIα on eosinophils increased eosinophil expressions of T cell costimulatory proteins CD40, CD80, and CD86. Humanized FcεRIα on murine eosinophils functions to enhance eosinophil antigen presentation capacities by mediating IgE-facilitated antigen presentation and upregulating expression of requisite T cell costimulatory proteins. Thus, a functional, non-“effector” role for FcεRI on eosinophils is revealed through identifying a means by which IgE may act on eosinophils to mediate their immunomodulatory, enhanced antigen presentation capabilities.


  • Open Access

    Extracellular sombrero vesicles are hallmarks of eosinophilic cytolytic degranulation in tissue sites of human diseases

    by Vitor H Neves, Cinthia Palazzi, Kássia K Malta, Kennedy Bonjour, Felipe Kneip, Felipe F Dias, Josiane S Neves, Peter F Weller, Rossana C N Melo

    Eosinophil sombrero vesicles are large tubular carriers resident in the cytoplasm of human eosinophils, identifiable by transmission electron microscopy, and important for immune mediator transport. Increased formation of sombrero vesicles occurs in activated eosinophils in vitro and in vivo. In tissue sites of eosinophilic cytolytic inflammation, extracellular eosinophil sombrero vesicles are noted, but their frequency and significance in eosinophil-associated diseases remain unclear. Here, we performed comprehensive quantitative transmission electron microscopy analyses and electron tomography to investigate the numbers, density, integrity, and 3-dimensional structure of eosinophil sombrero vesicles in different biopsy tissues from 5 prototypic eosinophil-associated diseases (eosinophilic chronic rhinosinusitis/nasal sinuses, ulcerative colitis/intestines, hypereosinophilic syndrome/skin, dermatitis/skin, and schistosomiasis/rectum). The morphology of extracellular eosinophil sombrero vesicles was also compared with that of cytoplasmic eosinophil sombrero vesicles, isolated by subcellular fractionation from peripheral blood eosinophils. We demonstrated that (i) eosinophil cytolysis, releasing intact sombrero vesicles and membrane-bound granules, is a consistent event in all eosinophil-associated diseases; (ii) eosinophil sombrero vesicles persist intact even after complete disintegration of all cell organelles, except granules (late cytolysis); (iii) the eosinophil sombrero vesicle population, composed of elongated, curved, and typical sombreros, and the eosinophil sombrero vesicle 3-dimensional architecture, diameter, and density remain unchanged in the extracellular matrix; (iv) free eosinophil sombrero vesicles closely associate with extracellular granules; and (v) free eosinophil sombrero vesicles also associate with externalized chromatin during eosinophil ETosis. Remarkably, eosinophil sombrero vesicles appeared on the surface of other cells, such as plasma cells. Thus, eosinophil cytolysis/ETosis can secrete intact sombrero vesicles, alongside granules, in inflamed tissues of eosinophil-associated diseases, potentially serving as propagators of eosinophil immune responses after cell death.


  • Urine eosinophil‐derived neurotoxin: A potential marker of activity in select eosinophilic disorders

    by Michelle A. Makiya, Paneez Khoury, Fei Li Kuang, Alexis Dominique Mata, Sana Mahmood, Abbie Bowman, David Espinoza, Nicholas Kovacs, Thomas Brown, Nicole Holland, et al.

    Background: Biomarkers of eosinophilic disease activity, especially in the context of novel therapies that reduce blood eosinophil counts, are an unmet need. Absolute eosinophil count (AEC) does not accurately reflect tissue eosinophilia or eosinophil activation. Therefore, the aims of this study were to compare the reliability of plasma and urine eosinophil major basic protein 1, eosinophil cationic protein, eosinophil‐derived neurotoxin (EDN), and eosinophil peroxidase measurement and to evaluate the usefulness of eosinophil granule protein (EGP) measurement for the assessment of disease activity in patients with eosinophil‐associated diseases treated with mepolizumab, benralizumab, or dexpramipexole.Methods: Eosinophil granule protein concentrations were measured in serum, plasma, and urine from healthy volunteers and patients with hypereosinophilic syndrome (HES), eosinophilic granulomatosis with polyangiitis (EGPA), and eosinophilic asthma using a multiplex assay.Results: Urine EGP concentrations remained stable, whereas serum and plasma EGP concentrations increased significantly with delayed processing. Plasma (p) EDN, but not urine (u) EDN, concentration correlated with AEC and negatively correlated with prednisone dose. Both pEDN and uEDN decreased significantly following treatment of HES patients with benralizumab and EGPA patients with mepolizumab. uEDN appeared to increase with clinical relapse in both patient groups.Conclusions: Measurement of EGP in urine is noninvasive and unaffected by cellular lysis. Although plasma and urine EDN concentrations showed a similar pattern following benralizumab and mepolizumab treatment, the lack of correlation between AEC or prednisone dose and uEDN concentrations suggests that measurement of uEDN may provide a potential biomarker of disease activity in patients with HES and EGPA.


  • Eosinophils as secretory cells

    by Rossana C.N. Melo, Ann M. Dvorak, Peter F. Weller


  • Eosinophil-associated diseases (EADs)

    by Rossana C.N. Melo, Ann M. Dvorak, Peter F. Weller


  • Top Cited Papers
    Open Access

    Eosinophils in Health and Disease: A State-of-the-Art Review

    by Michael E. Wechsler, Ariel Munitz, Steven J. Ackerman, Matthew G. Drake, David J. Jackson, Andrew J. Wardlaw, Stephanie K. Dougan, Sergejs Berdnikovs, Florence Schleich, Andrea Matucci, et al.


  • Open Access

    Donald J. Krogstad, MD (1943–2020), Physician-Scientist, Malaria Researcher, and Mentor

    by Ousmane Koita, Seydou Doumbia, Richard Oberhelman, Peter Weller, Joseph Keating, Thomas Eisele

  • The Charcot–Leyden crystal protein revisited—A lysopalmitoylphospholipase and more

    by Peter F Weller, Haibin Wang, Rossana C N Melo

    The Charcot–Leyden crystal protein (CLC-P), a constituent of human and not mouse eosinophils, is one of the most abundant proteins within human eosinophils. It has a propensity to form crystalline structures, Charcot–Leyden crystals, which are hallmarks in their distinctive extracellular crystalline forms as markers of eosinophilic inflammation. The functions of CLC-P within eosinophils have been uncertain. Although the action of CLC-P as a lysophospholipase has been questioned, assays of chromatographically purified CLC-P and crystal-derived CLC-P as well as studies of transfected recombinant CLC-P have consistently documented that CLC-P endogenously expresses lysophospholipase activity, releasing free palmitate from substrate lysopalmitoylphosphatidylcholine. Rather than acting solely as a hydrolytic enzyme to release palmitate from a lysolipid substrate, some other lysophospholipases function more dominantly as acyl-protein thioesterases (APTs), enzymes that catalyze the removal of thioester-linked, long chain fatty acids, such as palmitate, from cysteine residues of proteins. As such APTs participate in palmitoylation, a post-translational modification that can affect membrane localization, vesicular transport, and secretion. CLC-P has attributes of an APT. Thus, whereas CLC-P expresses inherent lysophospholipase activity, like some other lysophospholipase enzymes, it likely also functions in regulating the dynamic palmitoylation cycle, including, given its dominant subplasmalemmal location, at the human eosinophil’s plasma membrane.